Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
Eli Lilly Stock Is Trading Down Thursday: What’s Behind The Move?
